Reports total group sales GBP7.66B. Pharmaceuticals sales GBP 4.2 billion, +4% AER, +2% CER; Vaccines GBP 1.5 billion, +23% AER, +20% CER; Consumer Healthcare GBP 2.0 billion, flat AER, +1% CER. Total Group operating margin 18.6%. Adjusted Group operating margin 28.2%, +1.6 percentage points AER, +1.0 percentage point CER. Emma Walmsley, CEO, GSK said: “We have made a strong start to 2019, which is an important year of execution for GSK, with growth in sales, operating margins and earnings per share in Q1, in line with our expectations. Strengthening our pipeline remains our number one priority and we reported positive data for several potential new medicines in HIV and Oncology during the quarter. I am also pleased to report that integration planning for our new proposed Consumer Healthcare business is going well and, subject to relevant approvals, we continue to expect to complete this transaction in the second half of the year. We look forward to building on the progress made this quarter.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.